Table 3.
Effects of MSC-EXO on epigenetics.
| Disease | Study model | Function | Reference |
|---|---|---|---|
| Inflammatory bowel disease | In vivo model/mice | Inhibits the phosphorylation of IκBα | (70) |
| Inflammatory bowel disease |
In vivo model/BABL/C mice In vitro model/FHC |
Inhibits ERK phosphorylation | (72) |
| Inflammatory bowel disease | In vivo model/C57BL/6J mice | Decreases the expression of miR-1246 | (10, 73) |
| Osteoarthritis |
In vivo model/mice In vitro model/Primary chondrocytes |
Regulates DNA methylation of miR-124 promoter | (86) |
| Osteoarthritis | A sample of articular cartilage from a patient with OA knee joint. Normal cartilage samples were taken from patients with no history of OA or rheumatoid arthritis | Upregulates the expression of miR-92a-3p | (87–89) |
| Osteoarthritis | Human clinical samples | Upregulates the expression of circRNA-0001236 | (91) |
| Osteoarthritis |
In vivo model/SD rats at 12 weeks old In vitro model/BMSC |
Inhibits the expression of miR-100-5P | (92) |
| Systemic lupus erythematosus |
In vivo model/C3MRL-Faslpr/J(MRL/lpr) In vitro model/BMSC |
Reduces the levels of miR-29b | (107) |
| Acute liver injury | In vivo model/C57BL/6 J mice | Mediates SAC7A11 deubiquitination | (109) |
| Liver damage |
In vivo model/C57BL/6 mice In vitro model/THP-1 |
Promotes the expression of miR-4553p | (110) |
| Acute spinal cord injury |
In vivo model/C57BL/6 mice In vitro model/HT-22 and HEK-293 T |
Promotes the expression of lncGm36569 | (111) |
| Atherosclerosis | Clinical samples In vivo model/ApoE−/− mice In vitro model/HUV-EC-C |
Triggers the release of lncRNA and regulates TEAD1 expression | (112) |
| Psoriasis |
In vivo model/C57BL/6 mice In vivo model/HaCaTcells |
Inhibits the phosphorylation of STAT3 | (113) |
| Pancreatic ductal adenocarcinoma |
In vivo model/BALB/c mice In vivo model/PANC-1(CL-0184)and CFPAC-1(CL-0059) |
Regulates the DNA methylation of S100A11 | (114) |